TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02826876

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical use
Description: Topical use of Ropivacaine in laparoscopic surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical use
Description: Topical use of Ropivacaine in laparoscopic surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laparoscopic repair of inguinal hernia
Description: intra-operative treatment with ropivacaine Vs placebo in laparoscopic repair of inguinal hernia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laparoscopic repair of inguinal hernia
Description: intra-operative treatment with ropivacaine Vs placebo in laparoscopic repair of inguinal hernia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laparoscopic bariatric surgery
Description: intra-operative treatment with ropivacaine Vs placebo in laparoscopic bariatric surgery
Study: NCT02627248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 70 mg/m² ivdrip, d1 for both TEC and ET regimes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 70 mg/m² ivdrip, d1 for both TEC and ET regimes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m² ivdrip, d2 for both TEC and ET regimes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m² ivdrip, d2 for both TEC and ET regimes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m² ivdrip, d2 for both TEC and ET regimes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m² ivdrip, d2 for both TEC and ET regimes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m² ivdrip, d2 for TEC regimes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m² ivdrip, d2 for TEC regimes
Study: NCT04514068

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: In each session, acupuncture are applied unilaterally or bilaterally on P6 acupoint. Each acupuncture needle will be stimulated by transcutaneous electric device.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: In each session, acupuncture are applied unilaterally or bilaterally on P6 acupoint. Each acupuncture needle will be stimulated by transcutaneous electric device.
Study: NCT02826876

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laparoscopic bariatric surgery
Description: intra-operative treatment with ropivacaine Vs placebo in laparoscopic bariatric surgery
Study: NCT04514068

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sham acupuncture
Study: NCT04645966

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: Neisseria meningitis groups A, B, C W, and Y vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: Neisseria meningitis groups A, B, C W, and Y vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: Neisseria meningitis groups A, B, C W, and Y vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: Neisseria meningitis groups A, B, C W, and Y vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: Neisseria meningitis groups A, B, C W, and Y vaccine
Study: NCT03677531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: Watch video of choice during RT
Study: NCT01182675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant Conditioning with Mobilization Only
Description: Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0 Transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant Conditioning with Mobilization and Alemtuzumab
Description: Day -7: Alemtuzumab 0.3 mg test dose then 0.3 mg/kg IV; Day -6: Alemtuzumab 0.3 mg/kg IV; Day -5: Alemtuzumab 0.3 mg/kg IV; Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0: Transplant
Study: NCT03326102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP107
Description: DHP107 200mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Paclitaxel
Description: IV Paclitaxel 80 mg/m2 QW (3 weeks on/1 week off)
Study: NCT03315624

Intervention type: DEVICE
Group type: OTHER
Intervention: Dialyzer
Description: Three hemodiafiltration sessions assigned to one type of dialyzer FX Coral 600, FX 600 and FX CorDiax 600
Study: NCT03435861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-745
Description: active drug capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules
Study: NCT01663532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole IM Depot
Study: NCT04599062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Talimogene Laherparepvec
Study: NCT01663532

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT05731778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride Toothpaste
Description: 0.454% stannous fluoride toothpaste

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colgate fluoride toothpaste
Description: 0.76 % Sodium MonoFluorophosphate (MFP)
Study: NCT03848117

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cyriax approach i.e. DTF massage and Mill's manipulation
Description: Each patient in group I i.e. Cyriax group was given 20-minute session. Each session started in sitting position and initially deep transverse friction massage was done at lateral compartment of the elbow joint and immediately after that mill's manipulation at elbow joint with flexion at wrist joint in pronated arm position. This session was repeated three times a week for one month (Total 12 sessions/ one month).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mulligan approach i.e. Taping and MWM
Description: Each patient in group II i.e. Mulligan group was given 30 to 45-minute session. Each session started in sitting position and it included mobilization with movement which was given in such a way that initially lateral glide at elbow joint was performed and after holding it, I asked the patient to make a fist and open the fist. In this way, I repeated this procedure 36 times and after 12 repetitions, a short rest period was given. Taping was applied after mobilization around the elbow joint over extensor carpi radialis muscles. This session was repeated three times a week for one month (Total 12 sessions/ one month).
Study: NCT01481727

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: BiPAP Pro 2, Phillips Respironics
Description: mechanical ventilation type bilevel at high intensity (\>18mmHg) for at least six hours, nocturnal ventilation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiPAP Pro 2, Phillips Respironics
Description: mechanical ventilation type bilevel at high intensity (\>18mmHg) for at least six hours, nocturnal ventilation.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CPAP sham
Description: CPAP sham maneuver (IPAP less or equal to 4cmH2O)
Study: NCT03311724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT01633853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D2
Description: Treatment with Vit D2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1,25(OH)2 Vit D3
Description: Treatment with 1,25(OH)2 Vitamin D3(Rocaltrol).
Study: NCT01002027

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-Counselling
Description: Intervention entailed six sessions of counselling-CBT delivered either by a trained Nurse, or by a Psychologist. Sessions focussed on: psycho-education about PND, main issues of concern, assessment of symptom severity, problem solving. Behavioural interventions (pleasant activities, anxiety management, relaxation, relationship communication) were used together with cognitive interventions (understanding links between thoughts and feelings, increasing positive thoughts, challenging negative self-talk and unhelpful beliefs).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-Counselling
Description: Intervention entailed six sessions of counselling-CBT delivered either by a trained Nurse, or by a Psychologist. Sessions focussed on: psycho-education about PND, main issues of concern, assessment of symptom severity, problem solving. Behavioural interventions (pleasant activities, anxiety management, relaxation, relationship communication) were used together with cognitive interventions (understanding links between thoughts and feelings, increasing positive thoughts, challenging negative self-talk and unhelpful beliefs).
Study: NCT03539536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin
Description: Intravenous (IV) infusion
Study: NCT03663816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental foot device
Description: Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in healthy people.
Study: NCT04481867

Intervention type: PROCEDURE
Group type: OTHER
Intervention: densah bur
Description: osseodensification densah bur

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: densah bur
Description: osseodensification densah bur
Study: NCT01308060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: During part A, Azzalure will be administered at Baseline 60 Speywood units at canthal lines and compared with placebo.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04599062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talimogene Laherparepvec
Description: Talimogene Laherparepvec
Study: NCT00300391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: haloperidol
Description: Aim #1. To conduct a RCT of IV haloperidol vs. placebo for the treatment of delirium in mechanically ventilated ICU patients. Patients in the cohort study that go on to develop delirium will be enrolled in a RCT comparing treatment with scheduled haloperidol vs. placebo. By comparing differences between treatment and placebo groups, we will test the hypothesis that treatment with scheduled haloperidol improves the primary outcome of 28-day and 90 day mortality and secondary outcomes of total delirium days, duration of mechanical ventilation, and ICU length of stay.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: control arem
Study: NCT02025621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT01594281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: Pre-filled syringe for intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: Pre-filled syringe for intravitreal injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal laser photocoagulation
Description: PRP treatment following DRS guidelines

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal laser photocoagulation
Description: PRP treatment following DRS guidelines
Study: NCT02397967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessments
Description: Neuropsychological assessments:~Intelligence Quotient (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette test, Lobrot test, Odedys test. Visio-spatial skill (JLO, Thurston, Corsi tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neuropsychological assessments
Description: Neuropsychological assessments:~Intelligence Quotient (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette test, Lobrot test, Odedys test. Visio-spatial skill (JLO, Thurston, Corsi tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)
Study: NCT04253470

Intervention type: OTHER
Intervention: embryo transfer
Description: Step of the assisted reproduction in which embryos are placed into the uterus in order to obtain a pregnancy

Intervention type: OTHER
Intervention: embryo transfer
Description: Step of the assisted reproduction in which embryos are placed into the uterus in order to obtain a pregnancy
Study: NCT03961295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab SC
Description: Vedolizumab SC liquid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC
Description: Vedolizumab SC liquid.
Study: NCT01936272

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chhabra Shunt Placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ETV/CPC
Study: NCT04319770

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enamel matrix derivative (EMD)
Description: periodontal regenerative surgery with enamel matrix derivative (EMD) (control)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyaluronic acid (HA)
Description: periodontal regenerative surgery with hyaluronic acid (HA) (test)
Study: NCT04599972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSF-1
Description: One drop bilaterally twice daily for approximately 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: One drop bilaterally twice daily for approximately 2 weeks.
Study: NCT02907281

Intervention type: OTHER
Intervention: Observational
Description: Observational

Intervention type: OTHER
Intervention: Observational
Description: Observational
Study: NCT02597985

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prehabilitation
Description: Supervised exercise training intervention will include three sessions per week for four weeks at a Mayo Clinic system cardiac rehabilitation facility. The Rochester, Minnesota Cardiac Rehabilitation Program will provide guidance and oversight. Modes of aerobic exercise will include treadmill walking (the primary mode of training) supplemented with non-weight-bearing activities such as stationary cycling and combination arm/leg recumbent exercise (NuStep device), as needed. Intensity will be set using Borg Perceived Exertion Scale (RPE) ratings of 12-14 (somewhat hard), keeping patients below the threshold for more than mild angina.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Study: NCT00028795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01149772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACCESS
Description: Participants received 6 treatment sessions (2 core and 4 electives). The two core modules are increasing awareness and controlling physical and emotional symptoms. After completion of the core modules the participant was able to choose elective modules from Managing Physical Health, The Power of Thoughts, Increasing Pleasant Activities, and Relaxation. Participants were required to complete the first session in person and subsequent sessions participants had the option to complete in-person or over the phone. Participants also had the option to receive 2 brief follow-up booster calls to aid in reinforcing the changes made.
Study: NCT01659359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses and Lidocaine
Description: The samples were randomly allocated to use Virtual reality glasses and 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The samples were randomly allocated to use 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
Study: NCT02505802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BoNT-A injection
Description: In BoNT-A treatment group patients received 200 units BoNT-A injection in the triceps surae (150iu) and tibial muscle posterior (50iu).
Study: NCT00742040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril
Description: A rapid 3-day up-titration protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Captopril
Description: A slower 9-day up-titration protocol
Study: NCT00474006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arm II
Description: Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 90 mg/m2/d civ x 3 days
Study: NCT00432640

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound staging
Description: Endoscopic ultrasound staging with both EUS-FNA and EBUS-TBNA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical staging
Description: Surgical staging
Study: NCT03718273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month.~Patients with 75 or more years of age will receive an initial dose of 2.5 mg / twice a day, which can be increased to 5 mg / twice a day in week 7 and to 7.5 mg in month 1 if the tolerance has been good

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: The initial dose will be based on whether there are factors such as age over 80 years, weight less than 60 kg and creatinine clearance \<60ml / min, if there is no factor, the oral dose will be 0.25mg / 24h. If there are 2 factors, the dose will be 0.15 mg / 24 h. and if there are 2 or 3 factors, the dose will be 0.10 mg / 24 h.
Study: NCT02801006

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenfilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: contact lens
Study: NCT00552344

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cimzia
Description: * Active substance: Certolizumab Pegol~* Pharmaceutical form:first reconstituted, lyophilized powder formulation of CZP and after implementation of Amendment 2 (after 401 subjects were enrolled) prefilled syringe~* Concentration: 200 mg/ml~* Route of Administration: Subcutaneous use
Study: NCT03007628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magpro X100
Description: In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThymatronSystem Ⅳ Electroconvulsive System
Description: In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Participants will engage in their intpatient treatment program as-usual.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: Participants will engage in their intpatient treatment program as-usual.
Study: NCT00314054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCV-796
Description: HCV-796 1000mg single dose
Study: NCT03592394

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immersive Virtual Reality (Gear VR)
Description: Immersing the user in a total visual environment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immersive Virtual Reality (Gear VR)
Description: Immersing the user in a total visual environment.
Study: NCT00245349

Intervention type: PROCEDURE
Intervention: F-18 Fluorothymidine
Study: NCT01975376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bococizumab (PF-04950615)
Description: 150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
Study: NCT00003761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rV-DF3/MUC1
Description: - The starting dose for this Phase I study of rV-DF3/MUC1 will be 4.76 x 106 PFU.~-- Dose escalation will proceed with cohorts of at least 6 patients as follows: Per vaccination~* Level 1 4.76 x 106 PFU~* Level 2 4.76 x 107 PFU~* Level 3 4.76 x 108 PFU
Study: NCT02111629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole and Secnidazole
Study: NCT00904176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 20 mg, followed by 10 mg, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 20 mg, followed by 10 mg, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Tablets, Oral, 25 mg, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Tablets, Oral, 25 mg, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Tablets, Oral, 0.25, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Tablets, Oral, 0.25, Single Dose